Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila

Human Molecular Genetics

Volumn 12, Issue 11, 2003, Pages 1253-1260

  Nagai, Yoshitaka ^a   Fujikake, Nobuhiro ^b   Ohno, Katsuhito ^c,d   Higashiyama, Hiroyuki ^b   Popiel, Helena A ^a   Rahadian, Julia ^a   Yamaguchi, Masamitsu ^c   Strittmatter, Warren J ^e   Burke, James R ^e   Toda, Tatsushi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA BIOSCIENCE INSTITUTE   (Japan)

^c Faculty of Textile Science   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLUTAMINE; POLYGLUTAMINE BINDING PEPTIDE 1; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; COMBINATORIAL LIBRARY; COMPOUND EYE; CONTROLLED STUDY; DEATH; DEGENERATIVE DISEASE; DROSOPHILA; DRUG SELECTIVITY; EYE DISEASE; FEMALE; HUNTINGTON CHOREA; HYPOTHESIS; IN VIVO STUDY; INHERITANCE; LIFESPAN; MALE; NERVE DEGENERATION; NERVOUS SYSTEM; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; TANDEM REPEAT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DROSOPHILA; EMBRYO LOSS; EMBRYO, NONMAMMALIAN; EYE DISEASES; NERVOUS SYSTEM; NEURODEGENERATIVE DISEASES; OLIGOPEPTIDES; PEPTIDES; PROMOTER REGIONS (GENETICS);

ANIMALIA;

EID: 12444292683     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/ddg144     Document Type: Article

References (46)

1. Zoghbi, H.Y. and Orr, H.T. (2000) Glutamine repeats and neurodegeneration. A. Rev. Neurosci., 23, 217-247.
2. Gusella, J.F. and MacDonald, M.E. (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci., 1, 109-115.
3. Margolis, R.L. and Ross, C.A. (2001) Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases. Trends Mol. Med., 7, 479-482.
4. Li, X.J., Li, S.H., Sharp, A.H., Nucifora, F.C. Jr., Schilling, G., Lanahan, A., Worley, P., Snyder, S.H. and Ross, C.A. (1995) A huntingtin-associated protein enriched in brain with implications for pathology. Nature, 378, 398-402.
5. Burke, J.R., Enghild, J.J., Martin, M.E., Jou, Y.S., Myers, R.M., Roses, A.D., Vance, J.M. and Strittmatter, W.J. (1996) Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med., 2, 347-350.
6. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
7. McCampbell, A., Taylor, J.P., Taye, A.A., Robitschek, J., Li, M., Walcott, J., Merry, D., Chai, Y., Paulson, H., Sobue, G. et al. (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum. Mal. Genet., 9, 2197-2202.
8. Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S. and Kakizuka, A. (1996) Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo.Nat. Genet., 13, 196-202.
9. Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. and Bates, G.P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537-548.
10. DiFiglia, M., Sapp, E., Chase K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
11. Cummings, C.J., Mancini, M.A., Antalffy, B., DeFranco, D.B., Orr, H.T. and Zoghbi, H.Y. (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet., 19, 148-154.
12. Bence, N.F., Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 292, 1552-1555.
13. Chai, Y., Koppenhafer, S.L., Bonini, N.M. and Paulson, H.L. (1999) Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci., 19, 10338-10347.
14. II130, interfering with CREB-dependent transcription. Nat. Genet., 26, 29-36.
15. Nucifora, F.C., Jr., Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
16. Nagai, Y., Onodera, O., Chun, J., Strittmatter, W.J. and Burke, J.R. (1999) Expanded polyglutamine domain proteins bind neurofilament and alter the neurofilament network. Exp. Neurol., 155, 195-203.
17. Nagai, Y., Tucker, T., Ren, H., Kenan, D.J., Henderson, B.S., Keene, J.D., Strittmatter, W.J. and Burke, J.R. (2000) Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem., 275, 10437-10442.
18. Lecerf, J.M., Shirley, T.L., Zhu, Q., Kazantsev, A., Amersdorfer, P., Housman, D.E., Messer, A. and Huston, J.S. (2001) Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci. USA, 98, 4764-4769.
19. Heiser, V., Scherzinger, E., Boeddrich, A., Nordhoff, E., Lurz, R., Schugardt, N., Lehrach, H. and Wanker, E.E. (2000) Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy. Proc. Natl Acad. Sci. USA, 97, 6739-6744.
20. Warrick, J.M., Paulson, H.L., Gray-Board, G.L., Bui, Q.T., Fischbeck, K.H., Pittman, R.N. and Bonini, N.M. (1998) Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell, 93, 939-949.
21. Higashiyama, H., Hirose, F., Yamaguchi, M., Inoue, Y.H., Fujikake, N., Matsukage, A. and Kakizuka, A. (2002) Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration. Cell Death Differ., 9, 264-273.
22. Brand, A.H. and Perrimon, N. (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development, 118, 401-415.
23. Ren, H., Nagai, Y., Tucker, T., Strittmatter, W.J. and Burke, J.R. (2001) Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death. Biochem. Biophys. Res. Commun., 288, 703-710.
24. Quiring, R., Walldorf, U., Kloter, U. and Gehring, W.J. (1994) Homology of the eyeless gene of Drosophila to the Small eye gene in mice and Aniridia in humans. Science, 265, 785-789.
25. Halder, G., Callaerts, P., Flister, S., Walldorf, U., Kloter, U. and Gehring, W.J. (1998) Eyeless initiates the expression of both sine oculis and eyes absent during Drosophila compound eye development. Development, 125, 2181-2191.
26. Warrick, J.M., Chan, H.Y., Gray-Board, G.L., Chai, Y., Paulson, H.L. and Bonini, N.M. (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet., 23, 425-428.
27. Ross, C.A. (1997) Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron, 19, 1147-1150.
28. Kim, T.W. and Tanzi, R.E. (1998) Neuronal intranuclear inclusions in polyglutamine diseases: Nuclear weapons or nuclear fallout? Neuron, 21, 657-659.
29. Sherman, M.Y. and Goldberg, A.L. (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron, 29, 15-32.
30. Perutz, M.F. and Windle, A.H. (2001) Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature, 412, 143-144.
31. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C.M. and Stefani, M. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature, 416, 507-511.
32. Kazemi-Esfarjani, P. and Benzer, S. (2000) Genetic suppression of polyglutamine toxicity in Drosophila. Science, 287, 1837-1840.
33. Kobayashi, Y., Kume, A., Li, M., Doyu, M., Hata, M., Ohtsuka, K. and Sobue, G. (2000) Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem., 275, 8772-8778.
34. Carmichael, J., Chatellier, J., Woolfson, A., Milstein, C., Fersht, A.R. and Rubinsztein, D.C. (2000) Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl Acad. Sci. USA, 97, 9701-9705.
35. Khoshnan, A., Ko, J. and Patterson, P.H. (2002) Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl Acad. Sci. USA, 99, 1002-1007.
36. Kazemi-Esfarjani, P. and Benzer, S. (2002) Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. Hum. Mol. Genet., 11, 2657-2672.
37. Bates, G.P., Mangiarini, L. and Davies, S.W. (1998) Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathol., 8, 699-714.
38. Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57-66.
39. Schilling, G., Jinnah, H.A., Gonzales, V., Coonfield, M.L., Kim, Y., Wood, J.D., Price, D.L., Li, X.J., Jenkins, N., Copeland, N. et al. (2001) Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. Neurobiol. Dis., 8, 405-418.
40. Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Do, J., Sang, C., Kobayashi, Y., Doyu, M. and Sobue, G. (2001) Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum. Mol. Genet., 10, 1039-1048.
41. Sánchez, I., Mahlke, C. and Yuan, J. (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature, 421, 373-379.
42. Schwarze, S.R., Hruska, K.A. and Dowdy, S.F. (2000) Protein transduction: unrestricted delivery into all cells? Trends Cell Biol., 10, 290-295.
43. Soto, C., Sigurdsson, E.M., Morelli, L., Kumar, R.A., Castano, E.M. and Frangione, B. (1998) β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med., 4, 822-826.
44. Kazantsev, A., Walker, H.A., Slepko, N., Bear, J.E., Preisinger, E., Steffan, J.S., Zhu, Y.Z., Gertler, F.B., Housman, D.E., Marsh, J.L. et al. (2002) A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila.Nat. Genet., 30, 367-376.
45. Ellis, M., O'Neill, E. and Rubin, G. (1993) Expression of Drosophila glass protein and evidence for negative regulation of its activity in non-neuronal cells by another DNA-binding protein. Development, 119, 855-865.
46. Lin, D.M. and Goodman, C.S. (1994) Ectopic and increased expression of fasciclin II alters motoneuron growth cone guidance. Neuron, 13, 507-523.